PCSK9: a convertase that coordinates LDL catabolism

Abifadel, 2003, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat. Genet., 34, 154, 10.1038/ng1161

Zaid, 2008, Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration, Hepatology., 48, 646, 10.1002/hep.22354

Horton, 2007, Molecular biology of PCSK9: its role in LDL metabolism, Trends Biochem. Sci., 32, 71, 10.1016/j.tibs.2006.12.008

Seidah, 2003, The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation, Proc. Natl. Acad. Sci. USA., 100, 928, 10.1073/pnas.0335507100

Dewpura, 2008, PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans, FEBS J., 275, 3480, 10.1111/j.1742-4658.2008.06495.x

Benjannet, 2006, The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications, J. Biol. Chem., 281, 30561, 10.1074/jbc.M606495200

Mayne, 2008, Plasma PCSK9 levels are significantly modified by statins and fibrates in humans, Lipids Health Dis., 7, 22, 10.1186/1476-511X-7-22

Careskey, 2008, Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9, J. Lipid Res., 49, 394, 10.1194/jlr.M700437-JLR200

Lambert, 2008, Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment, Clin. Chem., 54, 1038, 10.1373/clinchem.2007.099747

Grefhorst, 2008, Plasma PCSK9 preferentially reduces liver LDL receptors in mice, J. Lipid Res., 49, 1303, 10.1194/jlr.M800027-JLR200

Maxwell, 2005, Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment, Proc. Natl. Acad. Sci. USA., 102, 2069, 10.1073/pnas.0409736102

Schmidt, 2008, Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo, Biochem. Biophys. Res. Commun., 370, 634, 10.1016/j.bbrc.2008.04.004

Brown, 2008, Cholesterol feedback: from Schoenheimer's bottle to Scap's MELADL, J. Lipid Res., S15

Jeong, 2008, Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2, J. Lipid Res., 49, 399, 10.1194/jlr.M700443-JLR200

Costet, 2006, Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c, J. Biol. Chem., 281, 6211, 10.1074/jbc.M508582200

Langhi, 2008, Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes, FEBS Lett., 582, 949, 10.1016/j.febslet.2008.02.038

Kourimate, 2008, Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9, J. Biol. Chem., 283, 9666, 10.1074/jbc.M705831200

Rudenko, 2002, Structure of the LDL receptor extracellular domain at endosomal pH, Science., 298, 2353, 10.1126/science.1078124

Zhang, 2007, Binding of proprotein convertase subtilisin/kexin yype 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation, J. Biol. Chem., 282, 18602, 10.1074/jbc.M702027200

Zhang, 2008, Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor, Proc. Natl. Acad. Sci. USA., 105, 13045, 10.1073/pnas.0806312105

Cunningham, 2007, Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia, Nat. Struct. Mol. Biol., 14, 413, 10.1038/nsmb1235

Fisher, 2007, Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation, J. Biol. Chem., 282, 20502, 10.1074/jbc.M701634200

Hampton, 2007, The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain, Proc. Natl. Acad. Sci. USA., 104, 14604, 10.1073/pnas.0703402104

Piper, 2007, The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol, Structure., 15, 545, 10.1016/j.str.2007.04.004

Kwon, 2008, Molecular basis for LDL receptor recognition by PCSK9, Proc. Natl. Acad. Sci. USA., 105, 1820, 10.1073/pnas.0712064105

McNutt, 2007, Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells, J. Biol. Chem., 282, 20799, 10.1074/jbc.C700095200

Poirier, 2008, The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2, J. Biol. Chem., 283, 2363, 10.1074/jbc.M708098200

Humphries, 2006, Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk, J. Med. Genet., 43, 943, 10.1136/jmg.2006.038356

Bottomley, 2009, Structural and biochemical characterization of the wild type PCSK9/EGF(AB) complex and natural familial hypercholesterolemia mutants, J. Biol. Chem., 284, 1313, 10.1074/jbc.M808363200

Pandit, 2008, Functional analysis of sites within PCSK9 responsible for hypercholesterolemia, J. Lipid Res., 49, 1333, 10.1194/jlr.M800049-JLR200

Bourbon, 2008, Familial hypercholesterolaemia in Portugal, Atherosclerosis., 196, 633, 10.1016/j.atherosclerosis.2007.07.019

Naoumova, 2005, Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response, Arterioscler. Thromb. Vasc. Biol., 25, 2654, 10.1161/01.ATV.0000190668.94752.ab

Cameron, 2008, Characterization of novel mutations in the catalytic domain of the PCSK9 gene, J. Intern. Med., 263, 420, 10.1111/j.1365-2796.2007.01915.x

Homer, 2008, Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa, Atherosclerosis., 196, 659, 10.1016/j.atherosclerosis.2007.07.022

McPherson, 2007, Statins for primary prevention of coronary artery disease, Lancet., 369, 1078, 10.1016/S0140-6736(07)60516-9

Kathiresan, 2008, A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction, N. Engl. J. Med., 358, 2299, 10.1056/NEJMc0707445

Willer, 2008, Newly identified loci that influence lipid concentrations and risk of coronary artery disease, Nat. Genet., 40, 161, 10.1038/ng.76

Folsom, 2007, Sequence variation in proprotein convertase subtilisin/kexin type 9 serine protease gene, low LDL cholesterol, and cancer incidence, Cancer Epidemiol. Biomarkers Prev., 16, 2455, 10.1158/1055-9965.EPI-07-0502

Hooper, 2007, The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population, Atherosclerosis., 193, 445, 10.1016/j.atherosclerosis.2006.08.039

Graham, 2007, Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice, J. Lipid Res., 48, 763, 10.1194/jlr.C600025-JLR200

Frank-Kamenetsky, 2008, Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates, Proc. Natl. Acad. Sci. USA., 105, 11915, 10.1073/pnas.0805434105

Qian, 2007, Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis, J. Lipid Res., 48, 1488, 10.1194/jlr.M700071-JLR200

Shan, 2008, PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide, Biochem. Biophys. Res. Commun., 375, 69, 10.1016/j.bbrc.2008.07.106

Jones, 2003, Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLER* Trial), Am. J. Cardiol., 92, 152, 10.1016/S0002-9149(03)00530-7

Hallman, 2007, Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from The Bogalusa Heart Study), Am. J. Cardiol., 100, 69, 10.1016/j.amjcard.2007.02.057

2001, 2863

Third report of the National Cholesterol Education Program (NCEP) expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002. 106: 3143–3421.

Hickman, 1998, Distributions and trends of serum lipid levels among United States children and adolescents ages 4–19 years: data from the Third National Health and Nutrition Examination Survey, Prev. Med., 27, 879, 10.1006/pmed.1998.0376